Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin

Drug	Drug Name	Drug Description
DB01268	Sunitinib	A receptor tyrosine kinase inhibitor and chemotherapeutic agent used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).

Drug	Drug Name	Target	Type
DB01268	Sunitinib	Platelet-derived growth factor receptor beta	target
DB01268	Sunitinib	Vascular endothelial growth factor receptor 1	target
DB01268	Sunitinib	Vascular endothelial growth factor receptor 2	target
DB01268	Sunitinib	Vascular endothelial growth factor receptor 3	target
DB01268	Sunitinib	Mast/stem cell growth factor receptor Kit	target
DB01268	Sunitinib	Receptor-type tyrosine-protein kinase FLT3	target
DB01268	Sunitinib	Macrophage colony-stimulating factor 1 receptor	target
DB01268	Sunitinib	Platelet-derived growth factor receptor alpha	target
DB01268	Sunitinib	Cytochrome P450 3A4	enzyme
DB01268	Sunitinib	Cytochrome P450 3A5	enzyme
DB01268	Sunitinib	Cytochrome P450 3A7	enzyme
DB01268	Sunitinib	Multidrug resistance-associated protein 4	transporter
DB01268	Sunitinib	P-glycoprotein 1	transporter
DB01268	Sunitinib	Canalicular multispecific organic anion transporter 1	transporter
DB01268	Sunitinib	ATP-binding cassette sub-family G member 2	transporter
DB01268	Sunitinib	Hepatocyte growth factor receptor	target

Drug	Drug Name	Phase	Status	Count